What is one of the risks associated with raloxifene in high-risk patients?

Raloxifene is a selective estrogen receptor modulator (SERM) commonly used for the prevention and treatment of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer. However, it has been associated with certain risks, particularly in high-risk patients.

Among those, the increased risk of death from stroke is notable in individuals who have a higher baseline risk for such cardiovascular events. The mechanism behind this association lies in the medication's effects on blood coagulation and vascular health. Raloxifene can lead to venous thromboembolism, impacting the overall cardiovascular profile of patients, especially those already predisposed to cardiovascular diseases.

In contrast, the other options reflect different risks. While raloxifene may affect cardiovascular events, increased risk of myocardial infarction is more associated with other medications, such as hormone replacement therapy. The link between raloxifene and breast cancer is minimal, as it actually has a protective effect against this type of cancer. Gastrointestinal bleeding is not a direct risk attributed to raloxifene use; rather, that risk is more connected to non-steroidal anti-inflammatory drugs or anticoagulants.

Understanding these associations is crucial for healthcare providers when considering the use of ral